Published in Infect Immun on December 10, 2007
Leishmania amazonensis promastigotes induce and are killed by neutrophil extracellular traps. Proc Natl Acad Sci U S A (2009) 2.68
Gene expression induced by Toll-like receptors in macrophages requires the transcription factor NFAT5. J Exp Med (2012) 1.28
Distinct roles for MyD88 and Toll-like receptor 2 during Leishmania braziliensis infection in mice. Infect Immun (2009) 1.24
Phosphoinositide 3-kinase-dependent inhibition of dendritic cell interleukin-12 production by Giardia lamblia. Infect Immun (2008) 1.13
The global cysteine peptidase landscape in parasites. Trends Parasitol (2009) 1.02
Role of Toll-like receptor 9 signaling in experimental Leishmania braziliensis infection. Infect Immun (2013) 0.97
Toll-like receptors participate in macrophage activation and intracellular control of Leishmania (Viannia) panamensis. Infect Immun (2011) 0.91
Two biochemically distinct lipophosphoglycans from Leishmania braziliensis and Leishmania infantum trigger different innate immune responses in murine macrophages. Parasit Vectors (2013) 0.89
TLR4 and NKT cell synergy in immunotherapy against visceral leishmaniasis. PLoS Pathog (2012) 0.87
Toll receptors type-2 and CR3 expression of canine monocytes and its correlation with immunohistochemistry and xenodiagnosis in visceral leishmaniasis. PLoS One (2011) 0.86
Toll-like receptors and CD40 modulate each other's expression affecting Leishmania major infection. Clin Exp Immunol (2014) 0.85
Glycoinositolphospholipids from Leishmania braziliensis and L. infantum: modulation of innate immune system and variations in carbohydrate structure. PLoS Negl Trop Dis (2012) 0.85
Regulatory actions of Toll-like receptor 2 (TLR2) and TLR4 in Leishmania donovani infection in the liver. Infect Immun (2013) 0.85
Immunoregulatory profile of monocytes from cutaneous leishmaniasis patients and association with lesion size. Parasite Immunol (2013) 0.84
Expression of Toll-like receptors 2 and 9 in cells of dog jejunum and colon naturally infected with Leishmania infantum. BMC Immunol (2013) 0.84
NK cell activity differs between patients with localized and diffuse cutaneous leishmaniasis infected with Leishmania mexicana: a comparative study of TLRs and cytokines. PLoS One (2014) 0.82
Enhanced expression of Toll-like receptors 2 and 4, but not 9, in spleen tissue from patients with visceral leishmaniasis. Parasite Immunol (2014) 0.80
The involvement of TLR2 and TLR4 in cytokine and nitric oxide production in visceral leishmaniasis patients before and after treatment with anti-leishmanial drugs. PLoS One (2015) 0.79
Anti-Toll-like receptor 2 and 4 antibodies suppress inflammatory response in mice. Immunology (2014) 0.79
Possibilities and challenges for developing a successful vaccine for leishmaniasis. Parasit Vectors (2016) 0.78
Leishmania enriettii: biochemical characterisation of lipophosphoglycans (LPGs) and glycoinositolphospholipids (GIPLs) and infectivity to Cavia porcellus. Parasit Vectors (2015) 0.78
The Roles of Mast Cells in Parasitic Protozoan Infections. Front Immunol (2017) 0.78
Identification of Th1/Th2 regulatory switch to promote healing response during leishmaniasis: a computational approach. EURASIP J Bioinform Syst Biol (2015) 0.77
Transcription of Toll-Like Receptors 2, 3, 4 and 9, FoxP3 and Th17 Cytokines in a Susceptible Experimental Model of Canine Leishmania infantum Infection. PLoS One (2015) 0.77
Insights on adaptive and innate immunity in canine leishmaniosis. Parasitology (2016) 0.77
Antileishmanial effect of 18β-glycyrrhetinic acid is mediated by Toll-like receptor-dependent canonical and noncanonical p38 activation. Antimicrob Agents Chemother (2015) 0.76
Enhanced survival of Leishmania major in neutrophil granulocytes in the presence of apoptotic cells. PLoS One (2017) 0.76
Signaling networks in Leishmania macrophages deciphered through integrated systems biology: a mathematical modeling approach. Syst Synth Biol (2013) 0.76
Local delivery of the TLR9 ligand, CpG, down-regulates host immune and inflammatory responses, ameliorating established Leishmania (Viannia) panamensis chronic infection. Infect Immun (2017) 0.75
Toll-like receptors in the brain of mice following infection with Acanthamoeba spp. Parasitol Res (2016) 0.75
Toll-Like Receptor 2 Is Required for Inflammatory Process Development during Leishmania infantum Infection. Front Microbiol (2017) 0.75
Cathepsin B-Deficient Mice Resolve Leishmania major Inflammation Faster in a T Cell-Dependent Manner. PLoS Negl Trop Dis (2016) 0.75
Mast cell activator compound 48/40 is not an effective adjuvant for UV-attenuated Toxoplasma gondii vaccine. Parasitol Res (2017) 0.75
Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature (2001) 25.15
Missing pieces in the NF-kappaB puzzle. Cell (2002) 17.83
Identification of Lps2 as a key transducer of MyD88-independent TIR signalling. Nature (2003) 10.97
Toll-like receptor signaling pathways. Science (2003) 5.86
The structure, biosynthesis and function of glycosylated phosphatidylinositols in the parasitic protozoa and higher eukaryotes. Biochem J (1993) 4.96
Mapping of the inducible IkappaB phosphorylation sites that signal its ubiquitination and degradation. Mol Cell Biol (1996) 4.56
IL-4 induces a Th2 response in Leishmania major-infected mice. J Immunol (1992) 4.43
Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clin Microbiol Rev (1997) 4.09
Cutting edge: MyD88 is required for resistance to Toxoplasma gondii infection and regulates parasite-induced IL-12 production by dendritic cells. J Immunol (2002) 3.12
A comprehensive map of the toll-like receptor signaling network. Mol Syst Biol (2006) 2.89
Activation of Toll-like receptor-2 by glycosylphosphatidylinositol anchors from a protozoan parasite. J Immunol (2001) 2.60
Role of Toll-like receptors in pathogen recognition. Clin Microbiol Rev (2003) 2.59
TLR3 in antiviral immunity: key player or bystander? Trends Immunol (2005) 2.40
Leishmaniases of the New World: current concepts and implications for future research. Clin Microbiol Rev (1993) 2.37
Subversion mechanisms by which Leishmania parasites can escape the host immune response: a signaling point of view. Clin Microbiol Rev (2005) 2.33
New world cutaneous leishmaniasis in travellers. Lancet Infect Dis (2006) 2.16
Leishmania lipophosphoglycan (LPG) activates NK cells through toll-like receptor-2. Mol Biochem Parasitol (2003) 2.08
Toll-like receptor (TLR) polymorphisms in African children: Common TLR-4 variants predispose to severe malaria. Proc Natl Acad Sci U S A (2005) 1.95
Toll-like receptor 2 is required for inflammatory responses to Francisella tularensis LVS. Infect Immun (2006) 1.93
The major surface protease (MSP or GP63) of Leishmania sp. Biosynthesis, regulation of expression, and function. Mol Biochem Parasitol (2003) 1.93
Genetically resistant mice lacking MyD88-adapter protein display a high susceptibility to Leishmania major infection associated with a polarized Th2 response. J Immunol (2003) 1.91
Persistence without pathology in phosphoglycan-deficient Leishmania major. Science (2003) 1.89
The role(s) of lipophosphoglycan (LPG) in the establishment of Leishmania major infections in mammalian hosts. Proc Natl Acad Sci U S A (2003) 1.89
MyD88 is essential for clearance of Leishmania major: possible role for lipophosphoglycan and Toll-like receptor 2 signaling. Eur J Immunol (2003) 1.82
Plasmodium berghei infection in mice induces liver injury by an IL-12- and toll-like receptor/myeloid differentiation factor 88-dependent mechanism. J Immunol (2001) 1.82
Transcriptional signaling by double-stranded RNA: role of TLR3. Cytokine Growth Factor Rev (2005) 1.80
Surface acid proteinase (gp63) of Leishmania mexicana. A metalloenzyme capable of protecting liposome-encapsulated proteins from phagolysosomal degradation by macrophages. J Biol Chem (1989) 1.78
The effect of post-bloodmeal nutrition of Phlebotomus papatasi on the transmission of Leishmania major. Am J Trop Med Hyg (1986) 1.78
Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents. Expert Opin Biol Ther (2004) 1.76
Developmental modification of lipophosphoglycan during the differentiation of Leishmania major promastigotes to an infectious stage. EMBO J (1992) 1.75
Toll-like receptor 4 contributes to efficient control of infection with the protozoan parasite Leishmania major. Infect Immun (2004) 1.65
TLR2 as an essential molecule for protective immunity against Toxoplasma gondii infection. Int Immunol (2003) 1.62
Mucosal leishmaniasis . Current scenario and prospects for treatment. Acta Trop (2007) 1.61
Parasite-accessory cell interactions in murine leishmaniasis. II. Leishmania donovani suppresses macrophage expression of class I and class II major histocompatibility complex gene products. J Immunol (1987) 1.60
NK cell activation in visceral leishmaniasis requires TLR9, myeloid DCs, and IL-12, but is independent of plasmacytoid DCs. J Exp Med (2007) 1.57
Toward an understanding of the biochemical and pharmacological complexity of the saliva of a hematophagous sand fly Lutzomyia longipalpis. Proc Natl Acad Sci U S A (1999) 1.57
Inhibition of phagolysosomal biogenesis by the Leishmania lipophosphoglycan. J Exp Med (1997) 1.54
Relationship between structures and biological activities of mycoplasmal diacylated lipopeptides and their recognition by toll-like receptors 2 and 6. Infect Immun (2004) 1.49
Expression of functional TLR4 confers proinflammatory responsiveness to Trypanosoma cruzi glycoinositolphospholipids and higher resistance to infection with T. cruzi. J Immunol (2004) 1.49
Double-stranded RNAs from the helminth parasite Schistosoma activate TLR3 in dendritic cells. J Biol Chem (2004) 1.44
Arachidonic acid metabolism by murine peritoneal macrophages infected with Leishmania donovani: in vitro evidence for parasite-induced alterations in cyclooxygenase and lipoxygenase pathways. J Immunol (1985) 1.43
Leishmania EF-1alpha activates the Src homology 2 domain containing tyrosine phosphatase SHP-1 leading to macrophage deactivation. J Biol Chem (2002) 1.42
RNA interference reveals a role for TLR2 and TLR3 in the recognition of Leishmania donovani promastigotes by interferon-gamma-primed macrophages. Eur J Immunol (2006) 1.41
Neutrophils activate macrophages for intracellular killing of Leishmania major through recruitment of TLR4 by neutrophil elastase. J Immunol (2007) 1.35
The glycoinositol phospholipids of Leishmania mexicana promastigotes. Evidence for the presence of three distinct pathways of glycolipid biosynthesis. J Biol Chem (1993) 1.35
Treatment of mucosal leishmaniasis in Latin America: systematic review. Am J Trop Med Hyg (2007) 1.30
Double-stranded RNA signaling by Toll-like receptor 3 requires specific tyrosine residues in its cytoplasmic domain. J Biol Chem (2002) 1.29
Role of the Toll/interleukin-1 receptor signaling pathway in host resistance and pathogenesis during infection with protozoan parasites. Immunol Rev (2004) 1.28
How protozoan parasites evade the immune response. Trends Parasitol (2002) 1.27
A simple purification of procyclic acidic repetitive protein and demonstration of a sialylated glycosyl-phosphatidylinositol membrane anchor. Biochem J (1993) 1.27
Defective stimulus-response coupling in human monocytes infected with Leishmania donovani is associated with altered activation and translocation of protein kinase C. Proc Natl Acad Sci U S A (1992) 1.26
Stimulus-response coupling in monocytes infected with Leishmania. Attenuation of calcium transients is related to defective agonist-induced accumulation of inositol phosphates. J Immunol (1992) 1.25
The comparative fine structure and surface glycoconjugate expression of three life stages of Leishmania major. Exp Parasitol (1991) 1.25
Myd88-dependent in vivo maturation of splenic dendritic cells induced by Leishmania donovani and other Leishmania species. Infect Immun (2004) 1.14
Dendritic cell (DC)-based protection against an intracellular pathogen is dependent upon DC-derived IL-12 and can be induced by molecularly defined antigens. J Immunol (2003) 1.14
Structure of Leishmania lipophosphoglycan: inter- and intra-specific polymorphism in Old World species. Biochem J (1995) 1.14
Immunotherapy for drug-refractory mucosal leishmaniasis. J Infect Dis (2006) 1.12
Leishmania promastigotes require lipophosphoglycan to actively modulate the fusion properties of phagosomes at an early step of phagocytosis. Cell Microbiol (2000) 1.12
Toll-like receptor recognition of Toxoplasma gondii. Int J Parasitol (2006) 1.11
Mucosal leishmaniasis: in situ characterization of the host inflammatory response, before and after treatment. Acta Trop (2003) 1.10
High levels of susceptibility and T helper 2 response in MyD88-deficient mice infected with Leishmania major are interleukin-4 dependent. Infect Immun (2003) 1.10
TLR4 agonists as immunomodulatory agents. J Endotoxin Res (2006) 1.09
Leucine-rich repeats in host-pathogen interactions. Arch Immunol Ther Exp (Warsz) (2004) 1.07
Leishmania major activates IL-1 alpha expression in macrophages through a MyD88-dependent pathway. Microbes Infect (2002) 1.07
Long-term control of Mycobacterium bovis BCG infection in the absence of Toll-like receptors (TLRs): investigation of TLR2-, TLR6-, or TLR2-TLR4-deficient mice. Infect Immun (2004) 1.06
Synthetic toll-like receptor 4 agonists stimulate innate resistance to infectious challenge. Infect Immun (2005) 1.04
Limits of a deletion spanning Tlr4 in C57BL/10ScCr mice. J Endotoxin Res (2000) 1.04
Characterization of glycoinositol phospholipids in the amastigote stage of the protozoan parasite Leishmania major. Biochem J (1993) 1.03
Leishmanial infection: analysis of its first steps. A review. Mem Inst Oswaldo Cruz (2004) 1.02
Infection of C57BL/10ScCr and C57BL/10ScNCr mice with Leishmania major reveals a role for Toll-like receptor 4 in the control of parasite replication. J Leukoc Biol (2004) 1.02
Two tyrosine residues of Toll-like receptor 3 trigger different steps of NF-kappa B activation. J Biol Chem (2006) 1.02
Inhibition of expression of major histocompatibility complex class II molecules in macrophages infected with Leishmania donovani occurs at the level of gene transcription via a cyclic AMP-independent mechanism. Infect Immun (1992) 1.01
Short report: quantification of leishmaniavirus RNA in clinical samples and its possible role in pathogenesis. Am J Trop Med Hyg (2003) 1.00
Leishmania, macrophages and complement: a tale of subversion and exploitation. Parasitology (1997) 0.98
IL-18 gene therapy develops Th1-type immune responses in Leishmania major-infected BALB/c mice: is the effect mediated by the CpG signaling TLR9? Gene Ther (2004) 0.97
Leishmania major surface protease Gp63 interferes with the function of human monocytes and neutrophils in vitro. APMIS (1994) 0.97
Chemokine gene expression in toll-like receptor-competent and -deficient mice infected with Leishmania major. Infect Immun (2004) 0.95
Leishmania infection and virulence. Med Microbiol Immunol (2001) 0.94
Cutaneous leishmaniasis reactivation 2 years after treatment caused by systemic corticosteroids - first report. Int J Dermatol (2007) 0.93
Toll-like receptor 4 (TLR4)-dependent proinflammatory and immunomodulatory properties of the glycoinositolphospholipid (GIPL) from Trypanosoma cruzi. J Leukoc Biol (2007) 0.92
DNA-Salmonella enterica serovar Typhimurium primer-booster vaccination biases towards T helper 1 responses and enhances protection against Leishmania major infection in mice. Infect Immun (2004) 0.92
Use of thermolytic protective groups to prevent G-tetrad formation in CpG ODN type D: structural studies and immunomodulatory activity in primates. Nucleic Acids Res (2006) 0.92
Mycobacterial lipomannan induces matrix metalloproteinase-9 expression in human macrophagic cells through a Toll-like receptor 1 (TLR1)/TLR2- and CD14-dependent mechanism. Infect Immun (2005) 0.91
Mutational and functional analysis of the Leishmania surface metalloproteinase GP63: similarities to matrix metalloproteinases. Parasitology (1994) 0.88
Leishmania major infection in C57BL/10 mice differing at the Lps locus: a new non-healing phenotype. Med Microbiol Immunol (1997) 0.88
Toll-like receptor ligands as adjuvants in allergen-specific immunotherapy. Clin Exp Allergy (2005) 0.87
Treatment of mucosal leishmaniasis with a lipid formulation of amphotericin B. Clin Infect Dis (2007) 0.86
Viral immunity: cross-priming with the help of TLR3. Curr Biol (2005) 0.83
Toxoplasma gondii inhibits toll-like receptor 4 ligand-induced mobilization of intracellular tumor necrosis factor alpha to the surface of mouse peritoneal neutrophils. Infect Immun (2006) 0.83
Leishmaniasis in Brazil: XXIII. The identification of Leishmania braziliensis braziliensis in wild-caught neotropical sandflies using monoclonal antibodies. Trans R Soc Trop Med Hyg (1987) 0.80
Immunology. Mouse studies question importance of toll-like receptors to vaccines. Science (2006) 0.79
Treatment of New World cutaneous leishmaniasis--a systematic review with a meta-analysis. Int J Dermatol (2008) 2.06
Risk factors for Chagas' disease reactivation after heart transplantation. J Heart Lung Transplant (2008) 1.55
Short report: persistence of tumor necrosis factor-alpha in situ after lesion healing in mucosal leishmaniasis. Am J Trop Med Hyg (2003) 1.06
Mucosal leishmaniasis and abnormalities on computed tomographic scans of paranasal sinuses. Am J Trop Med Hyg (2010) 0.95
High levels of T lymphocyte activation in Leishmania-HIV-1 co-infected individuals despite low HIV viral load. BMC Infect Dis (2010) 0.95
[A retrospective search for maternal transmission of Chagas infection from patients in the chronic phase]. Rev Soc Bras Med Trop (2005) 0.94
Decreased AIRE expression and global thymic hypofunction in Down syndrome. J Immunol (2011) 0.94
Cutaneous leishmaniasis reactivation 2 years after treatment caused by systemic corticosteroids - first report. Int J Dermatol (2007) 0.93
Probable recognition of human anisakiasis in Brazil. Rev Inst Med Trop Sao Paulo (2007) 0.93
IFNG +874T/A polymorphism is not associated with American tegumentary leishmaniasis susceptibility but can influence Leishmania induced IFN-gamma production. BMC Infect Dis (2007) 0.93
Evaluation of a recombinant Trypanosoma cruzi mucin-like antigen for serodiagnosis of Chagas' disease. Clin Vaccine Immunol (2011) 0.92
Ekbom syndrome (delusory parasitosis): ponderations on two cases. Rev Inst Med Trop Sao Paulo (2007) 0.87
Treatment of mucosal leishmaniasis with a lipid formulation of amphotericin B. Clin Infect Dis (2007) 0.86
[Antischistosomal activity of artemether in experimental Schistosomiasis mansoni]. Rev Saude Publica (2004) 0.85
Microwave treatment of human milk to prevent transmission of Chagas disease. Rev Inst Med Trop Sao Paulo (2003) 0.82
Origin of the "Y strain" of Trypanosoma cruzi. Rev Inst Med Trop Sao Paulo (2010) 0.80
[Alternative transmission mechanisms of Trypanosoma cruzi in Brazil and proposals for their prevention]. Rev Soc Bras Med Trop (2011) 0.79
[Treatment of chronic Chagas' disease with an association of nifurtimox and corticoid]. Rev Soc Bras Med Trop (2003) 0.79
[Prevention concerning the different alternative routes for transmission of Trypanosoma cruzi in Brazil]. Rev Soc Bras Med Trop (2011) 0.78
Discrepancies and consequences of indirect hemagglutination, indirect immunofluorescence and ELISA tests for the diagnosis of Chagas disease. Rev Inst Med Trop Sao Paulo (2012) 0.78
[Evaluation of the efficacy of azithromycin and pyrimethamine, for treatment of experimental infection of mice with Toxoplasma gondii cystogenic strain]. Rev Soc Bras Med Trop (2005) 0.77
Survival of Trypanosoma cruzi in sugar cane used to prepare juice. Rev Inst Med Trop Sao Paulo (2006) 0.77
Evaluation of the "Symbiosys" immunoassay for the serological diagnosis of Chagas disease. Rev Inst Med Trop Sao Paulo (2012) 0.76
Reactivation of Trypanosoma cruzi infection in immunosuppressed patients: contributions for the laboratorial diagnosis standardization. Rev Inst Med Trop Sao Paulo (2008) 0.76
[Observations on Blastocystis hominis and Cyclospora cayetanensis in routine parasitological examinations]. Rev Soc Bras Med Trop (2007) 0.76
[Chagas disease centenary]. Rev Saude Publica (2009) 0.76
Paragonimiasis in Brazil. Braz J Infect Dis (2008) 0.75
[Infectology dimension]. Rev Soc Bras Med Trop (2005) 0.75
Trypanosoma cruzi: the supposed removal of the use of the xenodiagnosis and blood culture. Rev Inst Med Trop Sao Paulo (2012) 0.75
[An evaluation of the efficacy of the CSF method for diagnosing intestinal helminthiases]. Rev Soc Bras Med Trop (2007) 0.75
[Evaluation of the humoral immune response to Strongyloides venezuelensis antigens]. Rev Soc Bras Med Trop (2009) 0.75
Abdominal ultrasound in the evaluation of fibrosis and portal hypertension in an area of schistosomiasis low endemicity. Rev Inst Med Trop Sao Paulo (2008) 0.75
[Dissemination of research results and knowledge through scientific journals]. Rev Soc Bras Med Trop (2002) 0.75
[Publishing papers]. Rev Soc Bras Med Trop (2008) 0.75
[Old infectology and new infectology: an extravagant conception]. Rev Soc Bras Med Trop (2005) 0.75
[Research: priorities to our public health]. Rev Saude Publica (2008) 0.75
[An AIDS patient with Trichoderma]. Rev Soc Bras Med Trop (2002) 0.75
[Pretentious and deified papers]. Rev Soc Bras Med Trop (2003) 0.75
[Behavior of the chemiluminescent ELISA method in relation to results considered discordant via three conventional techniques for diagnosing Chagas disease]. Rev Soc Bras Med Trop (2007) 0.75